GRA BLOG

March 27, 2020

Georgia Fights COVID-19

A quick rundown of impressive activities in university labs and startups

In ways imaginative and pragmatic, Georgia’s university scientists and startup companies have gotten into the fight against COVID-19.

Here are some examples of how GRA-backed researchers and entrepreneurs in our state are applying expertise and ingenuity against the coronavirus.

An experimental drug developed at Emory University to treat the COVID-19 disease is advancing toward human testing. The treatment is being licensed by Ridgeback Biotherapeutics through DRIVE, LLC, an Emory nonprofit working to bring the drug to market.

Read more >


January 29, 2020

Meeting of the magnificent minds

Our notebook from the 2020 Academy of GRA Eminent Scholars

Synthetic chemistry could yield compounds that defeat drug-resistant bacteria. Electrical power generation and distribution is changing at a staggering pace. Genetically identical twins experience high blood pressure differently.

Emerging drugs for cystic fibrosis will increase life expectancy by decades.

Read more >


October 2, 2019

Historic NIH research grants to UGA, Emory could exceed $200 million

Funding validates GRA's Eminent Scholar model

This week’s news that the National Institutes of Health (NIH) has awarded two Georgia universities major grants to advance work toward a universal flu vaccine is more than a testament to their sophisticated research programs. It also reflects how the Georgia Research Alliance’s efforts to recruit world-class scientists to Georgia can pay off in a big way.

On September 30, the University of Georgia and Emory University each announced it would play leadership roles in a nationwide effort to accelerate pursuit of the vaccine, considered the “Holy Grail” of influenza prevention. Combined, the NIH grants to the two institutions – made through its Collaborative Influenza Vaccine Innovation Centers (CIVICs) – could exceed $200 million in the years to come.

Read more >